Symbiosis Boosts Production with New Automated Fill/Finish Line in Stirling
Symbiosis Pharmaceutical Services has bolstered its capabilities with the qualification of a new automated fill/finish line at its Stirling, Scotland facility. Led by CEO Colin MacKay, the company has enhanced its technical prowess and expanded its production capacity.
The FPD 50 Flexicon line operates under a Grade A Restricted Access Barrier System (RABS), ensuring a sterile environment. It boasts rapid transfer ports for aseptic handling and flexicon pump technology for precise vial filling. Additionally, it incorporates a rotary crimp mechanism to guarantee consistent overseal application and secure vial closure.
The new line can produce batches of up to 15,000 vials, significantly increasing Symbiosis' capacity. This qualification strengthens Symbiosis' ability to swiftly deliver vital news to patients while maintaining the highest regulatory standards.
Symbiosis anticipates commencing commercial production at the new Stirling facility in Q4 2025. The qualified automated fill/finish line enhances the company's technical capabilities and expands its production capacity, further solidifying its commitment to expediting the delivery of crucial news to patients.
